These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

894 related articles for article (PubMed ID: 17666070)

  • 41. Nonverbal behavior during standardized interviews in patients with schizophrenia spectrum disorders.
    Brüne M; Sonntag C; Abdel-Hamid M; Lehmkämper C; Juckel G; Troisi A
    J Nerv Ment Dis; 2008 Apr; 196(4):282-8. PubMed ID: 18414122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
    Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
    J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testosterone in first-episode schizophrenia.
    Cesková E; Prikryl R; Kaspárek T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Schizophrenia-spectrum psychoses in people with and without intellectual disability.
    Bouras N; Martin G; Leese M; Vanstraelen M; Holt G; Thomas C; Hindler C; Boardman J
    J Intellect Disabil Res; 2004 Sep; 48(Pt 6):548-55. PubMed ID: 15312055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
    Wunderink L; Nienhuis FJ; Sytema S; Wiersma D
    Schizophr Bull; 2007 May; 33(3):792-6. PubMed ID: 16894026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
    Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
    Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
    Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
    Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One-year outcome and its prediction in first-episode schizophrenia--a naturalistic study.
    Bachmann S; Bottmer C; Schroder J
    Psychopathology; 2008; 41(2):115-23. PubMed ID: 18059113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drug treatment of schizophrenic psychoses in puerperium].
    Olbrich HM; Martin P
    Nervenarzt; 1994 Jul; 65(7):482-5. PubMed ID: 7800093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subjective assessments of the quality of life, well-being and self-efficacy in patients with schizophrenia.
    Chino B; Nemoto T; Fujii C; Mizuno M
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):521-8. PubMed ID: 19531107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
    J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reducing the dose of depot neuroleptics in stable schizophrenia.
    Dale R; Longdon M; Seeman MV
    J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.
    Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropsychological functions predict 1- and 3-year outcome in first-episode psychosis.
    Carlsson R; Nyman H; Ganse G; Cullberg J
    Acta Psychiatr Scand; 2006 Feb; 113(2):102-11. PubMed ID: 16423161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration of untreated psychosis and it's effect on the functional outcome in schizophrenia - preliminary results.
    Sarotar BN; Pesek MB; Agius M; Pregelj P; Kocmur M
    Psychiatr Danub; 2008 Jun; 20(2):179-83. PubMed ID: 18587288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duration of postictal psychotic episodes.
    Adachi N; Ito M; Kanemoto K; Akanuma N; Okazaki M; Ishida S; Sekimoto M; Kato M; Kawasaki J; Tadokoro Y; Oshima T; Onuma T
    Epilepsia; 2007 Aug; 48(8):1531-7. PubMed ID: 17386048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quetiapine in the treatment of psychotic adolescents: a case series of 23 patients with severe early onset psychosis.
    Beer F; Heinrich H; Springer S; Rüth U; Freisleder FJ
    World J Biol Psychiatry; 2007; 8(1):38-41. PubMed ID: 17366348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Remission after first-episode schizophrenia: results of a long-term follow-up.
    Üçok A; Serbest S; Kandemir PE
    Psychiatry Res; 2011 Aug; 189(1):33-7. PubMed ID: 21196051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic stability over 3 years in a total group of first-episode psychosis patients.
    Rahm C; Cullberg J
    Nord J Psychiatry; 2007; 61(3):189-93. PubMed ID: 17523030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.